MKI67 and neoplasm: Moreover, immunohistochemistry staining assays showed that Ki67, an indicator of tumor proliferation, was also notably reduced in the combination group compared with the control, Spautin-1 or Enzalutamide alone treatment groups (Fig. 8g and Additional file 1: Figure S5b).